Lord's Mark Industries, a renowned business is celebrating its 25 years of excellence, and has launched a new subsidiary called Lord's Mark Microbiotech. The subsidiary aims to champion genome testing in India through the introduction of their first online lab.

Lord's Mark Microbiotech, a new subsidiary, is introducing saliva-based technology for genome testing through its brand MyDNA, ensuring 99 percent accuracy. This innovative test eliminates the need for blood extraction or the presence of a phlebotomist. Individuals can easily perform the test at home by following the enclosed instructions in the kit.

Lord's Mark Microbiotech aims to make these products and cutting-edge genome testing technology accessible to people across the nation through healthcare providers and doctors. By visiting the company's website, individuals can conveniently order genome testing kits online, which will be delivered within 48 hours. After conducting the test, a reverse pick-up service will be provided.

In addition, Lord's Mark Industries possesses its patented algorithm, SNAPPY, which calculates the Polygenic Risk Score (PRS). This score estimates an individual's genetic predisposition or risk for a specific trait or condition by aggregating all known common variants associated with the disease.

During the event, Sachidanand Upadhyay, the Founder of Lord's Mark Industries, addressed the audience and expressed -

“Genome testing is an exciting new area with the potential to revolutionise healthcare in India. In this context, it is a matter of great pride that the launch of this new subsidiary coincides with the completion of 25 years of excellence in business by Lord’s Mark Industries. Lord’s Mark Microbiotech will focus on preventive Genomic testing for early detection, screening, and personalised interventions for diseases such as cancer, cardiovascular disorders, diabetes, or hereditary condition.”

The new subsidiary aims to provide accessible and affordable genome testing services in 48 cities across the nation. Initially, the focus will be on metro and tier 1 cities, followed by expansion to tier 2 and tier 3 towns over the next 3-4 years.

Subodh Gupta, the CEO of Lord's Mark Microbiotech, stated-

“We already have the technology for Genome testing. With the new subsidiary, we will focus on preventive Genomic testing for early detection, screening, and personalised interventions. The focus will also be on pharmacogenomics which can help optimise drug selection and dosages.”

The price range for the genome testing kits will range from Rs 8,000 to Rs 16,000. Additionally, the company plans to collaborate with leading scientific and research institutes to develop and implement diagnostic tools for diseases such as cancer and tuberculosis. It will initiate an initial investment of Rs 20 crore with a revenue target of Rs 100 crore within 5 years.

Resource - https://www.expresshealthcare.in/news/lords-mark-industries-launches-new-subsidiary/439804/